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Transcatheter aortic valve implantation (TAVI) has expanded
rapidly since the first procedure in 2002. The first randomised
control trial showed non inferiority of TAVI compared with
surgical aortic valve replacement (AVR) in high-risk patients
with severe aortic valve stenosis (AS) and superiority as
compared with conservative management, including balloon
valvuloplasty [1]. Since 2012, TAVI has been incorporated
into the international guidelines for treatment of severe AS for
symptomatic, high-risk patients. This technology has evolved
towards the routine therapy for high-risk patients with severe
AS over the past decade. Since its introduction, more than
100,000 transcatheter aortic valve implantations have been
performed worldwide.
Three major approaches have emerged, including the ret-
rograde transcatheter route (mainly transfemoral, subclavian,
axillary), the direct aortic approach via a mini-sternotomy, and
the antegrade transapical cardiac route via a small anterolateral
thoracotomy. The retrograde transfemoral approach is the
most frequently used technique. However, tortuosity and min-
imal vessel diameter of the peripheral artery tract are obstacles
for this approach.
The devices used for TAVI can be subdivided into two
groups: balloon-expandable and self-expandable prostheses.
The balloon expandable Edwards SAPIEN Transcatheter
Heart Valve (Edwards Lifesciences, Irvine, CA, USA) and
the self-expanding Medtronic CoreValve™ (Medtronic, Min-
neapolis, MN, USA) are the most frequently used prostheses.
In the current issue of the Netherlands Heart Journal,
Nijenhuis et al. describe their first experience with the
JenaValve [2]. The JenaValve is a self-expanding device that
received CE approval for AS in September 2011 and for aortic
regurgitation in September 2013. It is currently a transapical
positioned prosthesis, composed of a nitinol self-expanding
stent, and three native porcine aortic valves. The device pro-
vides the option of repetitive repositioning before final re-
lease. Rapid pacing is not necessary for positioning of this
prosthesis. The JenaValve contains a clipping system that
fixates the stent to the diseased native valve leaflets. This is
in contrast to the aforementioned Edwards SAPIEN and
Medtronic CoreValve devices, in which radial forces exerted
on the aortic annulus provide alignment and fixation.
The authors describe the procedural and 6-month results of
their first experience with implantation of the JenaValve.
Patients with severe aortic stenosis and severe peripheral
artery disease precluding the transfemoral approach were the
subject of the study. Somewhat surprisingly, patients with
aortic regurgitation were not included in this small cohort of
patients.
The prosthesis was implanted successfully in 21 patients
(88 %). There were no procedural deaths, conversions to
surgery, nor device malpositioning.
The rate of major bleeding was low, taking into account the
access route as well as the size of the delivery system. The
only case of major bleeding was gastrointestinal bleeding in
one patient.
One patient died during the 30-day follow-up period. It is
conceivable that the anchoring technology of the JenaValve is
associated with a low incidence of postprocedural cardiac
conduction disorders, since radial force is not exerted on the
aortic annulus or the endocardium. However, 12 patients de-
veloped a cardiac conduction disorder during hospitalisation.
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This may be due to the high rate of postdilatation (67 %) that
was apparently considered necessary to obtain a satisfactory
procedural result. The low rate of paravalvular leakage reported
with the JenaValve is promising as paravalvular leakage is a
known complication in TAVI. This is relevant since moderate-
to-severe paravalvular leakage is associated with an increase in
late mortality [3].
Technical refinements in TAVI are rapidly evolving. The
JenaValve has several advantages compared with the current
armamentarium of prostheses; a major advantage of this de-
vice is the approval not only for aortic stenosis, but for aortic
regurgitation. The initial experiences with this device for
treatment of pure aortic regurgitation have recently been re-
ported and preliminary results are promising [4]. Furthermore,
the device is retrievable, which potentially reduces the risk for
malpositioning and improves device success rate, compared
with irretrievable self-expandable prostheses.
The benefits of the JenaValve prosthesis are promising.
However, technical refinements of this device are man-
datory to penetrate in this highly competitive market.
These improvements of the device include downsizing
of the 32 Fr delivery system of the transapical device.
Furthermore the preferred approach in suitable patients
is the transfemoral route in contrast to the transapical
route. A transfemoral JenaValve is currently being eval-
uated in a multicentre first-in-men trial. The largest
series to date using the JenaValve involves 88 patients, 79
patients with severe aortic stenosis and 9 with severe aortic
regurgitation. This German experience reports a device suc-
cess of 91 %, and a 30-day mortality of 10 % [4]. The
experience described in this issue of the Netherlands Heart
Journal is in line with previous results.
The improvement in the technology of transcatheter aortic
valve implantation, including an optimised, balanced anti-
thrombotic treatment regimen postprocedurally [5], will result
in an expansion of clinical indications such as lower risk and
younger patients who may benefit from this treatment, show-
ing excellent long-term outcomes. Furthermore, TAVI can be
used for aortic regurgitation, with devices such as the
JenaValve. However, data on long-term follow-up are essen-
tial to assess the safety and durability of new devices for
expanding current indications in this rapidly changing area
of transcatheter valve implantations.
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